APLS management is making excuses vis-à-vis the Syfovre launch, but the real problem (IMO) is that the drug simply isn’t that good: https://www.fiercepharma.com/pharma/apellis-cites-current-challenges-syfovre-launch-bright-prospects-long-term See #msg-171260849 for related info.